Automated neuroradiological support systems for multiple cerebrovascular disease markers -- A systematic review and meta-analysis
Cerebrovascular diseases (CVD) can lead to stroke and dementia. Stroke is the second leading cause of death world wide and dementia incidence is increasing by the year. There are several markers of CVD that are visible on brain imaging, including: white matter hyperintensities (WMH), acute and chron...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal Article |
| Language: | English |
| Published: |
22-10-2024
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Cerebrovascular diseases (CVD) can lead to stroke and dementia. Stroke is the
second leading cause of death world wide and dementia incidence is increasing
by the year. There are several markers of CVD that are visible on brain
imaging, including: white matter hyperintensities (WMH), acute and chronic
ischaemic stroke lesions (ISL), lacunes, enlarged perivascular spaces (PVS),
acute and chronic haemorrhagic lesions, and cerebral microbleeds (CMB). Brain
atrophy also occurs in CVD. These markers are important for patient management
and intervention, since they indicate elevated risk of future stroke and
dementia. We systematically reviewed automated systems designed to support
radiologists reporting on these CVD imaging findings. We considered
commercially available software and research publications which identify at
least two CVD markers. In total, we included 29 commercial products and 13
research publications. Two distinct types of commercial support system were
available: those which identify acute stroke lesions (haemorrhagic and
ischaemic) from computed tomography (CT) scans, mainly for the purpose of
patient triage; and those which measure WMH and atrophy regionally and
longitudinally. In research, WMH and ISL were the markers most frequently
analysed together, from magnetic resonance imaging (MRI) scans; lacunes and PVS
were each targeted only twice and CMB only once. For stroke, commercially
available systems largely support the emergency setting, whilst research
systems consider also follow-up and routine scans. The systems to quantify WMH
and atrophy are focused on neurodegenerative disease support, where these CVD
markers are also of significance. There are currently no openly validated
systems, commercially, or in research, performing a comprehensive joint
analysis of all CVD markers (WMH, ISL, lacunes, PVS, haemorrhagic lesions, CMB,
and atrophy). |
|---|---|
| DOI: | 10.48550/arxiv.2410.17124 |